Gabexate mesilate, a new synthetic serine protease inhibitor: a pilot clinical trial in valvular heart surgery.
To assess the effects of gabexate mesilate ([GM], Foy, ONO Pharmaceutical Co, Osaka, Japan) on blood loss in cardiac valve replacement surgery and to establish whether GM reduces blood loss or transfusion requirements after this surgery. Randomized single-blind trial in 30 patients receiving either GM (2 mg/kg/h in a central venous catheter), or no GM, after heparin. Department of Anesthesia and Intensive Care, Cardiac Surgery, in a hospital in Italy. Consent patients. Cardiac valve replacement surgery. Intraoperative and postoperative bleeding, blood transfusion, hemoglobin, and hematocrit were compared. In the GM group bleeding was reduced and no transfusions were required. GM appears to play a useful role in reducing blood loss during extracorporeal circulation in cardiac surgery.